Cis-dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas.
cis-Dichlorodiammineplatinum(II) was given to 13 patients with metastatic sarcomas following failure in two previous chemotherapy protocols. Two of these patients had complete regression which lasted 6 months in one patient and is still present after 8 months in the other. One patient had a greater than 50% regression which lasted 5 months. Three patients had disease stabilization for 2 months each. cis-Dichlorodiammineplatinum(II), as a single agent, was well-tolerated with no significant renal or auditory toxicity.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin